Cuda is a specialty pharmaceutical development company whose lead product is an improved formulation of the general anesthetic Propofol. The market for Propofol is large ($200-$300m) with only one meaningful player, and there has been a history of product shortages due to contamination issues with other formulations. Cuda's development plan for Propofol is short, simple and inexpensive ($2.5m) for such a high value 505(b)2 NDA.